Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? Yes
Write-up: liver tumour; Condition worsened; Ascites; This is a spontaneous report from a non-contactable physician downloaded from the regulatory authority case identification number: DE-DCGMA-21192052, Safety Report Unique Identifier DE-PEI-202100192193. An 81-year-old male patient received bnt162b2 (COMIRNATY), first dose, via an unspecified route of administration on 05May2021 at the age of 81 years old, as single dose for covid-19 immunisation. Medical history included previously inconspicuous liver tumour. There were no concomitant medications. The patient experienced liver tumour on 15Jul2021, condition worsened on 15Jul2021, ascites on 15Jul2021. The patient died on an unspecified date. It was not reported if an autopsy was performed. This report is serious - death, life threatening. Source of assessment: PEI. Result of Assessment was unclassifiable. Reporter''s comments: ADR: Comirnaty first vaccination, followed by development of fulminant course of a previously inconspicuous liver tumour with ascites, rapid physical deterioration until death. No follow-up attempts are possible. No further information is expected. Information on batch/lot number cannot be obtained.; Reporter''s Comments: ADR: Comirnaty first vaccination, followed by development of fulminant course of a previously inconspicuous liver tumour with ascites, rapid physical deterioration until death.; Reported Cause(s) of Death: Ascites; Condition aggravated; Hepatic neoplasm
Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166